XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (20,699,000) $ (16,757,000)
Adjustment to reconcile net loss to net cash used in operating activities:    
In-process research and development impairment charge 5,700,000 0
Non-cash stock-based compensation 1,011,000 578,000
Non-cash lease expense 173,000 95,000
Change in fair value of contingent consideration (4,337,000) (279,000)
Change in fair value of common stock warrants (15,000) 97,000
Deferred income taxes (239,000) (23,000)
Changes in operating assets and liabilities:    
Contract asset 1,128,000 282,000
Prepaid expenses and other assets (1,174,000) 84,000
Accounts payable (2,513,000) (836,000)
Accrued expenses and other current liabilities 727,000 742,000
Operating lease liabilities (183,000) 0
Deferred revenue (5,600,000) 5,600,000
Net cash used in operating activities (26,021,000) (10,417,000)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 9,005,000 29,599,000
Proceeds from exercise of warrants 3,069,000 8,535,000
Collection of stock subscription receivable 0 308,000
Net cash provided by financing activities 12,074,000 38,442,000
Net increase (decrease) in cash, cash equivalents, restricted cash, and restricted cash equivalents (13,947,000) 28,025,000
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of year 35,402,000 7,377,000
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of year 21,455,000 35,402,000
Supplemental disclosure of cash flow information:    
Cash received during the year for interest 6,000 26,000
Supplemental disclosures:    
Contract asset within accounts payable 0 1,410,000
Reclassification of warrant liabilities upon exercise 0 94,000
Deferred offering costs included in accounts payable and accrued expenses 0 181,000
Right-of-use assets recorded $ 0 $ 976,000